The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a phase II study.
Daniel J. George
Research Funding - Millennium
Paul G. Corn
No relevant relationships to disclose
M. Dror Michaelson
Consultant or Advisory Role - Millennium (U)
Research Funding - Millennium
Hans J. Hammers
No relevant relationships to disclose
Joshi J. Alumkal
No relevant relationships to disclose
Charles J. Ryan
Honoraria - Millennium
Justine Yang Bruce
No relevant relationships to disclose
Susan Moran
Employment or Leadership Position - Millennium
Stock Ownership - Millennium
Shih-Yuan Lee
Employment or Leadership Position - Millennium
Peter Mortimer
Employment or Leadership Position - Takeda Global RD London
Maha Hussain
No relevant relationships to disclose